tiprankstipranks
Trending News
More News >
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
US Market

Protagonist Therapeutics (PTGX) Financial Statements

Compare
726 Followers

Protagonist Therapeutics Financial Overview

Protagonist Therapeutics's market cap is currently $5.15B. The company's EPS TTM is $-0.62; its P/E ratio is 126.62; Protagonist Therapeutics is scheduled to report earnings on November 6, 2025, and the estimated EPS forecast is $-0.34. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue$ 434.43M$ 60.00M$ 26.58M$ 27.36M$ 28.63M
Gross Profit$ 434.43M$ 60.00M$ 26.58M$ 27.36M$ 28.63M
Operating Income$ 252.84M$ -93.65M$ -131.37M$ -125.84M$ -64.52M
EBITDA$ 253.67M$ -90.34M$ -128.00M$ -123.07M$ -63.57M
Net Income$ 275.19M$ -78.95M$ -127.39M$ -125.55M$ -66.15M
Balance Sheet
Cash & Short-Term Investments$ 418.91M$ 341.62M$ 237.35M$ 326.90M$ 305.81M
Total Assets$ 744.73M$ 357.95M$ 247.93M$ 347.69M$ 324.47M
Total Debt$ 10.87M$ 1.14M$ 3.66M$ 5.86M$ 5.96M
Net Debt$ -86.38M$ -185.59M$ -122.09M$ -117.81M$ -111.40M
Total Liabilities$ 69.43M$ 21.27M$ 32.32M$ 47.67M$ 44.86M
Stockholders' Equity$ 675.29M$ 336.68M$ 215.61M$ 300.02M$ 279.61M
Cash Flow
Free Cash Flow$ 182.80M$ -70.84M$ -108.93M$ -108.97M$ -72.95M
Operating Cash Flow$ 184.15M$ -70.24M$ -108.14M$ -107.86M$ -72.48M
Investing Cash Flow$ -299.48M$ -39.26M$ 91.47M$ -15.86M$ -90.97M
Financing Cash Flow$ 25.85M$ 170.48M$ 18.84M$ 129.92M$ 247.63M
Currency in USD

Protagonist Therapeutics Earnings and Revenue History

Protagonist Therapeutics Debt to Assets

Protagonist Therapeutics Cash Flow

Protagonist Therapeutics Forecast EPS vs Actual EPS